Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 23, 2019
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Li Xuan, Yu Wang, Jia Chen, et al.
Oncoimmunology
|
July 29, 2016
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation
Xinmiao Jiang, Lanping Xu, Yu Zhang, et al.
BMC Medicine
|
September 1, 2022
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial
Xin Xu, Zhiping Fan, Yu Wang, et al.
Leukemia
|
November 18, 2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study
Hui Liu, Li Xuan, Ren Lin, et al.
Cancer
|
March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
Xiaoxia Chen, Junwei Huang, Na Xu, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2024
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia
Zhao Yin, Zurong Yao, Dandan Chen, et al.
The Lancet. Haematology
|
January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial
Li Xuan, Min Dai, Erlie Jiang, et al.
American Journal of Hematology
|
November 16, 2024
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph<sup>+</sup> acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study
Hui Liu, Hui Xu, Peiru Chi, et al.
The Lancet. Oncology
|
August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan, Yu Wang, Fen Huang, et al.
Blood Cancer Journal
|
February 19, 2025
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Rongtao Xue, Min Dai, Erlie Jiang, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 23, 2019
Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Li Xuan, Yu Wang, Jia Chen, et al.
Oncoimmunology
|
July 29, 2016
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation
Xinmiao Jiang, Lanping Xu, Yu Zhang, et al.
BMC Medicine
|
September 1, 2022
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial
Xin Xu, Zhiping Fan, Yu Wang, et al.
Leukemia
|
November 18, 2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study
Hui Liu, Li Xuan, Ren Lin, et al.
Cancer
|
March 22, 2022
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
Xiaoxia Chen, Junwei Huang, Na Xu, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2024
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia
Zhao Yin, Zurong Yao, Dandan Chen, et al.
The Lancet. Haematology
|
January 26, 2023
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial
Li Xuan, Min Dai, Erlie Jiang, et al.
American Journal of Hematology
|
November 16, 2024
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph<sup>+</sup> acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study
Hui Liu, Hui Xu, Peiru Chi, et al.
The Lancet. Oncology
|
August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan, Yu Wang, Fen Huang, et al.
Blood Cancer Journal
|
February 19, 2025
Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Rongtao Xue, Min Dai, Erlie Jiang, et al.
Page
of 6